Renal cancer

Enrichetta Corgna, Maura Betti, Gemma Gatta, Fausto Roila, P. H M De Mulder

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

In Europe, renal cancer (that is neoplasia of the kidney, renal pelvis or ureter (ICD-9 189 and ICD-10 C64-C66)) ranks as the seventh most common malignancy in men amongst whom there are 29,600 new cases each year (3.5% of all cancers). Tobacco, obesity and a diet poor in vegetables are all acknowledged risk factors, along with specific occupational and environmental factors. A familial history of renal carcinoma is also likely to increase the risk. Renal carcinoma may remain clinically occult for most of its course. The classic presentation of pain, haematuria, and flank mass occurs in only 9% of patients and is often indicative of advanced disease. Approximately 30% of patients with renal carcinoma present with metastatic disease, 25% with locally advanced renal carcinoma and 45% with localized disease. Metastases are typically found in the lung, soft tissue, bone, liver, cutaneous sites, and central nervous system. The most important staging technique is a computed tomography (CT) scan of the whole abdomen. Survival rates are more favourable for patients with tumours confined to the kidney. Five-year survival for patients with metastatic renal carcinoma is comprised between 0 and 20%. Radical nephrectomy is the standard intervention for renal cancer. Intrinsic resistance to chemotherapy has long been a hallmark of renal carcinoma. Limited options are available for the systemic therapy, and no chemotherapeutic regimen is accepted as a standard of care. Biologic agents represent the major effective therapies for widespread metastatic renal cancer. An antiangiogenic strategy, the neutralization of VEGF, can slow the growth rate of advanced cancer.

Original languageEnglish
Pages (from-to)247-262
Number of pages16
JournalCritical Reviews in Oncology/Hematology
Volume64
Issue number3
DOIs
Publication statusPublished - Dec 2007

Fingerprint

Kidney Neoplasms
Kidney
Carcinoma
Kidney Pelvis
International Classification of Diseases
Neoplasms
Flank Pain
Biological Factors
Hematuria
Standard of Care
Ureter
Nephrectomy
Vegetables
Abdomen
Vascular Endothelial Growth Factor A
Tobacco
Survival Rate
Central Nervous System
Obesity
Tomography

Keywords

  • Radical nephrectomy
  • Renal cancer
  • Survival

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Corgna, E., Betti, M., Gatta, G., Roila, F., & De Mulder, P. H. M. (2007). Renal cancer. Critical Reviews in Oncology/Hematology, 64(3), 247-262. https://doi.org/10.1016/j.critrevonc.2007.04.007

Renal cancer. / Corgna, Enrichetta; Betti, Maura; Gatta, Gemma; Roila, Fausto; De Mulder, P. H M.

In: Critical Reviews in Oncology/Hematology, Vol. 64, No. 3, 12.2007, p. 247-262.

Research output: Contribution to journalArticle

Corgna, E, Betti, M, Gatta, G, Roila, F & De Mulder, PHM 2007, 'Renal cancer', Critical Reviews in Oncology/Hematology, vol. 64, no. 3, pp. 247-262. https://doi.org/10.1016/j.critrevonc.2007.04.007
Corgna, Enrichetta ; Betti, Maura ; Gatta, Gemma ; Roila, Fausto ; De Mulder, P. H M. / Renal cancer. In: Critical Reviews in Oncology/Hematology. 2007 ; Vol. 64, No. 3. pp. 247-262.
@article{2be0234c5b134ab390254065fb262190,
title = "Renal cancer",
abstract = "In Europe, renal cancer (that is neoplasia of the kidney, renal pelvis or ureter (ICD-9 189 and ICD-10 C64-C66)) ranks as the seventh most common malignancy in men amongst whom there are 29,600 new cases each year (3.5{\%} of all cancers). Tobacco, obesity and a diet poor in vegetables are all acknowledged risk factors, along with specific occupational and environmental factors. A familial history of renal carcinoma is also likely to increase the risk. Renal carcinoma may remain clinically occult for most of its course. The classic presentation of pain, haematuria, and flank mass occurs in only 9{\%} of patients and is often indicative of advanced disease. Approximately 30{\%} of patients with renal carcinoma present with metastatic disease, 25{\%} with locally advanced renal carcinoma and 45{\%} with localized disease. Metastases are typically found in the lung, soft tissue, bone, liver, cutaneous sites, and central nervous system. The most important staging technique is a computed tomography (CT) scan of the whole abdomen. Survival rates are more favourable for patients with tumours confined to the kidney. Five-year survival for patients with metastatic renal carcinoma is comprised between 0 and 20{\%}. Radical nephrectomy is the standard intervention for renal cancer. Intrinsic resistance to chemotherapy has long been a hallmark of renal carcinoma. Limited options are available for the systemic therapy, and no chemotherapeutic regimen is accepted as a standard of care. Biologic agents represent the major effective therapies for widespread metastatic renal cancer. An antiangiogenic strategy, the neutralization of VEGF, can slow the growth rate of advanced cancer.",
keywords = "Radical nephrectomy, Renal cancer, Survival",
author = "Enrichetta Corgna and Maura Betti and Gemma Gatta and Fausto Roila and {De Mulder}, {P. H M}",
year = "2007",
month = "12",
doi = "10.1016/j.critrevonc.2007.04.007",
language = "English",
volume = "64",
pages = "247--262",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - Renal cancer

AU - Corgna, Enrichetta

AU - Betti, Maura

AU - Gatta, Gemma

AU - Roila, Fausto

AU - De Mulder, P. H M

PY - 2007/12

Y1 - 2007/12

N2 - In Europe, renal cancer (that is neoplasia of the kidney, renal pelvis or ureter (ICD-9 189 and ICD-10 C64-C66)) ranks as the seventh most common malignancy in men amongst whom there are 29,600 new cases each year (3.5% of all cancers). Tobacco, obesity and a diet poor in vegetables are all acknowledged risk factors, along with specific occupational and environmental factors. A familial history of renal carcinoma is also likely to increase the risk. Renal carcinoma may remain clinically occult for most of its course. The classic presentation of pain, haematuria, and flank mass occurs in only 9% of patients and is often indicative of advanced disease. Approximately 30% of patients with renal carcinoma present with metastatic disease, 25% with locally advanced renal carcinoma and 45% with localized disease. Metastases are typically found in the lung, soft tissue, bone, liver, cutaneous sites, and central nervous system. The most important staging technique is a computed tomography (CT) scan of the whole abdomen. Survival rates are more favourable for patients with tumours confined to the kidney. Five-year survival for patients with metastatic renal carcinoma is comprised between 0 and 20%. Radical nephrectomy is the standard intervention for renal cancer. Intrinsic resistance to chemotherapy has long been a hallmark of renal carcinoma. Limited options are available for the systemic therapy, and no chemotherapeutic regimen is accepted as a standard of care. Biologic agents represent the major effective therapies for widespread metastatic renal cancer. An antiangiogenic strategy, the neutralization of VEGF, can slow the growth rate of advanced cancer.

AB - In Europe, renal cancer (that is neoplasia of the kidney, renal pelvis or ureter (ICD-9 189 and ICD-10 C64-C66)) ranks as the seventh most common malignancy in men amongst whom there are 29,600 new cases each year (3.5% of all cancers). Tobacco, obesity and a diet poor in vegetables are all acknowledged risk factors, along with specific occupational and environmental factors. A familial history of renal carcinoma is also likely to increase the risk. Renal carcinoma may remain clinically occult for most of its course. The classic presentation of pain, haematuria, and flank mass occurs in only 9% of patients and is often indicative of advanced disease. Approximately 30% of patients with renal carcinoma present with metastatic disease, 25% with locally advanced renal carcinoma and 45% with localized disease. Metastases are typically found in the lung, soft tissue, bone, liver, cutaneous sites, and central nervous system. The most important staging technique is a computed tomography (CT) scan of the whole abdomen. Survival rates are more favourable for patients with tumours confined to the kidney. Five-year survival for patients with metastatic renal carcinoma is comprised between 0 and 20%. Radical nephrectomy is the standard intervention for renal cancer. Intrinsic resistance to chemotherapy has long been a hallmark of renal carcinoma. Limited options are available for the systemic therapy, and no chemotherapeutic regimen is accepted as a standard of care. Biologic agents represent the major effective therapies for widespread metastatic renal cancer. An antiangiogenic strategy, the neutralization of VEGF, can slow the growth rate of advanced cancer.

KW - Radical nephrectomy

KW - Renal cancer

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=35649026216&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35649026216&partnerID=8YFLogxK

U2 - 10.1016/j.critrevonc.2007.04.007

DO - 10.1016/j.critrevonc.2007.04.007

M3 - Article

VL - 64

SP - 247

EP - 262

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

IS - 3

ER -